全文获取类型
收费全文 | 187666篇 |
免费 | 12873篇 |
国内免费 | 730篇 |
专业分类
耳鼻咽喉 | 2570篇 |
儿科学 | 5359篇 |
妇产科学 | 3776篇 |
基础医学 | 23952篇 |
口腔科学 | 3870篇 |
临床医学 | 18619篇 |
内科学 | 40245篇 |
皮肤病学 | 3036篇 |
神经病学 | 18767篇 |
特种医学 | 6572篇 |
外国民族医学 | 21篇 |
外科学 | 27993篇 |
综合类 | 2507篇 |
现状与发展 | 3篇 |
一般理论 | 201篇 |
预防医学 | 13986篇 |
眼科学 | 5045篇 |
药学 | 12258篇 |
中国医学 | 201篇 |
肿瘤学 | 12288篇 |
出版年
2023年 | 674篇 |
2021年 | 2763篇 |
2020年 | 1857篇 |
2019年 | 3075篇 |
2018年 | 3603篇 |
2017年 | 2614篇 |
2016年 | 3011篇 |
2015年 | 3649篇 |
2014年 | 5365篇 |
2013年 | 8242篇 |
2012年 | 11927篇 |
2011年 | 12829篇 |
2010年 | 7116篇 |
2009年 | 6572篇 |
2008年 | 11990篇 |
2007年 | 12831篇 |
2006年 | 12304篇 |
2005年 | 12668篇 |
2004年 | 12091篇 |
2003年 | 11509篇 |
2002年 | 11029篇 |
2001年 | 1892篇 |
2000年 | 1440篇 |
1999年 | 1821篇 |
1998年 | 2019篇 |
1997年 | 1722篇 |
1996年 | 1428篇 |
1995年 | 1611篇 |
1994年 | 1479篇 |
1993年 | 1391篇 |
1992年 | 1324篇 |
1991年 | 1255篇 |
1990年 | 1124篇 |
1989年 | 1101篇 |
1988年 | 1057篇 |
1987年 | 957篇 |
1986年 | 1071篇 |
1985年 | 1161篇 |
1984年 | 1375篇 |
1983年 | 1290篇 |
1982年 | 1693篇 |
1981年 | 1560篇 |
1980年 | 1441篇 |
1979年 | 962篇 |
1978年 | 1025篇 |
1977年 | 906篇 |
1976年 | 789篇 |
1975年 | 698篇 |
1974年 | 740篇 |
1973年 | 601篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
1.
2.
Improving hyperpolarized 129Xe ADC mapping in pediatric and adult lungs with uncertainty propagation
3.
4.
5.
6.
7.
Loren Saulsberry PhD Ankur Bhargava MD MPH Sharon Zeng BA Jason B. Gibbons PhD Cody Brannan MS Diane S. Lauderdale PhD Robert D. Gibbons PhD 《Health services research》2023,58(4):873-881
Objective
To derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level.Data Sources and Study Setting
The most recent releases of secondary, publicly available data were collected from national U.S. health agencies as well as state and city public health departments.Study Design
The Social Vulnerability Metric (SVM) was constructed from U.S. zip-code level measures (2018) from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality (2016), COVID-19 vaccination (2021), and emergency department visits for asthma (2018). The SVM was also compared with the existing Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) to determine convergent validity and differential predictive validity.Data Collection/Extraction Methods
The data were collected directly from published files available to the public online from national U.S. health agencies as well as state and city public health departments.Principal Findings
The correlation between SVM scores and national age-adjusted county all-cause mortality was r = 0.68. This correlation demonstrated the SVM's robust validity and outperformed the SVI with an almost four-fold increase in explained variance (46% vs. 12%). The SVM was also highly correlated (r ≥ 0.60) to zip-code level health outcomes for the state of California and city of Chicago.Conclusions
The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions. The SVM provides a single measure of SDoH that better quantifies associations with health outcomes. 相似文献8.
Stefaniuk Catherine M. Schlegelmilch June Meyerson Howard J. Harding Clifford V. Maitta Robert W. 《Journal of thrombosis and thrombolysis》2022,53(4):950-953
Journal of Thrombosis and Thrombolysis - Over the last few years data from our group have indicated that α-synuclein is important in development of immune cells as well as potentially... 相似文献
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.